Itraconazole and clinical and radiologic findings in patients with recurrent chronic rhinosinusitis and nasal polyposis

Phase 2

Conditions: Condition 1: nasal polyposis. Condition 2: Chronic rhinitis.
Nasal polyp
Chronic rhinitis

Registration Number: IRCT201211062106N4

Lead Sponsor: Isfahan University of Medical Sciences, Vice Challenry

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 22

Inclusion Criteria

The inclusion criteria contained patients at least 15 years old without history of hepatic disease and heart failure; without allergy to Itraconazole, and usage of interacting medications (cisapride, dofetilide, ergot derivatives, levomethadyl lovastatin, midazolam (oral), nisoldipine, pimozide, quinidine, simvastatin, or triazolam). Exclusion criteria of the study were no compliance for follow up; side effects of Itraconazole like rising in hepatic enzyme; nausea, vomiting or starting a new treatment during the study.

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of rhinorrhea, nasal obstruction, hyposmia, dyspnea. Timepoint: 0, 1st, 3rd and 6th months. Method of measurement: Asking the patient about the score of none, mild, moderate and severe.

Secondary Outcome Measures

Name	Time	Method
Quality of life. Timepoint: 0,1st, 3rd and 6th months. Method of measurement: SNOT-20.;Serum IgE. Timepoint: 0 and 3rd months. Method of measurement: Unit.;Score of CT scan. Timepoint: 0 and 3rd months. Method of measurement: Lund-Mackay scale.;Side effects like elevated liver enzyme, diarrhea and nausea. Timepoint: 0,1st, 3rd and 6th months. Method of measurement: Ask a patient.